We are live on ! Find out more
RCM

RA Capital Management Portfolio holdings

AUM $9.44B
1-Year Est. Return 157.3%
This Fund
S&P 500
This Quarter Est. Return
+17.81%
1 Year Est. Return
+157.3%
3 Year Est. Return
+589.39%
5 Year Est. Return
+654.96%
10 Year Est. Return
+50,915.53%
AUM
$5.3B
AUM Growth
+$879M
Cap. Flow
+$397M
Cap. Flow %
7.5%
Top 10 Hldgs %
58.3%
Holding
63
New
4
Increased
10
Reduced
3
Closed
9

Top Buys

Rank Stock Value
1
ASND icon
Ascendis Pharma A/S
ASND
+$371M
2
LEGN icon
Legend Biotech
LEGN
+$250M
3
AXSM icon
Axsome Therapeutics
AXSM
+$73.8M
4
NAMS icon
NewAmsterdam Pharma
NAMS
+$66.3M
5
FDMT icon
4D Molecular Therapeutics
FDMT
+$56.5M

Top Sells

Rank Stock Value
1
IMGN
Immunogen Inc
IMGN
+$231M
2
BLU
BELLUS Health Inc.
BLU
+$91M
3
CLDX icon
Celldex Therapeutics
CLDX
+$62.4M
4
HLVX
HilleVax
HLVX
+$29.1M
5
KNTE
Kinnate Biopharma Inc. Common Stock
KNTE
+$26.7M

Sector Composition

Rank Sector Weight
1 Healthcare 99.99%
Name Market Value Portfolio Weight Shares or Principal Change
in Stake 		Capital Flow
CNTB
51
Connect Biopharma Holdings
CNTB
$127M
$7.9M 0.15%
6,991,003
– –
TRML
52
DELISTED
Tourmaline Bio
TRML
$7.09M 0.13%
+233,318
New +$5.96M
NSTG
53
DELISTED
NanoString Technologies, Inc.
NSTG
$6.98M 0.13%
1,723,373
-733,900
-30% -$5.42M
NAMSW icon
54
NewAmsterdam Pharma Warrant
NAMSW
$697K 0.01%
333,333
– –
CLDX icon
55
Celldex Therapeutics
CLDX
$2.99B
– –
-1,734,972
Closed -$62.4M
ENTX icon
56
Entera Bio
ENTX
$147M
– –
-295,966
Closed -$343K
HLVX
57
DELISTED
HilleVax
HLVX
– –
-1,760,019
Closed -$29.1M
RCKT icon
58
Rocket Pharmaceuticals
RCKT
$340M
– –
-1,131,775
Closed -$19.4M
WHWK
59
Whitehawk Therapeutics
WHWK
$190M
– –
-590,218
Closed -$4.27M
FUSN
60
DELISTED
Fusion Pharmaceuticals Inc. Common Shares
FUSN
– –
-659,992
Closed -$2.49M
KNTE
61
DELISTED
Kinnate Biopharma Inc. Common Stock
KNTE
– –
-4,264,144
Closed -$26.7M
BLU
62
DELISTED
BELLUS Health Inc.
BLU
– –
-12,643,574
Closed -$91M
STSA
63
DELISTED
Satsuma Pharmaceuticals, Inc. Common Stock
STSA
– –
-5,914,252
Closed -$4.13M
1 2
3

Similar funds

RCMNY
Rubric Capital Management (New York) New York $9.44B AUM 68.42% 1-Year Est. Return
SCM
SCS Capital Management Boston, Massachusetts $9.44B AUM 18.1% 1-Year Est. Return
SIM
SRS Investment Management New York $9.47B AUM 60.12% 1-Year Est. Return
NPT
National Philanthropic Trust Jenkintown, Pennsylvania $9.38B AUM 33.37% 1-Year Est. Return
AC
Allstate Corporation Northbrook, Illinois $9.35B AUM 16.13% 1-Year Est. Return
PVI
Partners Value Investments Hamilton, Bermuda $9.34B AUM 12.2% 1-Year Est. Return
WPL
WINDACRE PARTNERSHIP LLC Houston, Texas $9.34B AUM 17.41% 1-Year Est. Return
BAMF
BI Asset Management Fondsmaeglerselskab Kobenhavn, Denmark $9.55B AUM 31.94% 1-Year Est. Return

RA Capital Management's Q2 2023 Portfolio in Review

As of Q2 2023, RA Capital Management held 63 positions worth $5.3B, up 20% from $4.42B the previous quarter. Its ten largest holdings account for 58% of the portfolio.

RA Capital Management deployed $397M of net new capital in Q2 2023, opening 4 new positions and adding to 10 existing holdings. Its largest new stake was Axsome Therapeutics: 1,000,000 shares worth $71.9M.

By sector, the portfolio is most concentrated in Healthcare at 100% of assets, up from 100% a quarter earlier.

On the sell side, the largest reduction was Immunogen Inc, an estimated $231M trimmed.

  • RA Capital Management's largest Q2 2023 buy was Axsome Therapeutics: 1,000,000 shares worth $71.9M.
  • RA Capital Management added most to Ascendis Pharma A/S in Q2 2023, an estimated $371M increase.
  • RA Capital Management's biggest Q2 2023 reduction was Immunogen Inc, cutting an estimated $231M.
  • RA Capital Management fully exited BELLUS Health Inc. in Q2 2023, selling an estimated $91M.
  • RA Capital Management's ten largest holdings make up 58% of its $5.3B portfolio in Q2 2023.
  • RA Capital Management opened 4 new positions and closed 9 in Q2 2023.
  • RA Capital Management's portfolio value rose 20% quarter-over-quarter to $5.3B.

Based on RA Capital Management's 13F filing for Q2 2023, filed 14 Aug 2023.